Today on The Fundamentals is Dr. Maria Castro, the R.C. Schneider collegiate professor of neurosurgery, and a professor of cell and developmental biology at the University of Michigan Medical School. Her research program aims to develop immunotherapies for primary and metastatic brain cancer, studying basic immune biology mechanisms leading to clinical implementation. She has been inducted into the American Association for the Advancement of Sciences, the Latin American Academy of Sciences, and the American Institute for Medical and Biological Engineering College of Fellows. She has won numerous awards for her contributions to basic science and cancer research and is a diversity ambassador for the Cancer Biology Graduate Training Program. You can learn more about Dr. Castro here, and you can follow her @castro2355_mg, the Rogel Cancer Center @UMRogelCancer, the department of neurosurgery @umichneuro, Michigan Neurscience Institute @UM_MNI and the department of cell and developmental biology @UMCDB on X

Four faculty and two staff members from the departments of Anesthesiology, Neurology, Radiology and Surgery, and the Office of Graduate Medical Education (GME), are recipients of GME Awards for 2024

As guest editor for a themed journal issue, Lori Pierce helps highlight the multiple factors that can make cancer care and prevention more equitable and reduce the burden of this disease for all

Vaccination against the coronavirus was much lower in adults and children with sickle cell disease despite a higher risk of severe COVID-19.

Research from Michigan Medicine experts is shedding light and potentially expanding options for patients living with an aggressive childhood cancer.

Babies born with sickle cell disease face social inequality as well as a lifelong chronic disease that is often undertreated with proven drugs.

Recently approved by the Food and Drug Administration, Pluvicto is a radionuclide-labelled drug administered to patients showing promising results.

A car accident at age 20 left Sahar Mashhour in the intensive care unit for three months. Almost six years later, Mashhour is still pursuing her passions proving that her disability doesn’t limit her ability, but instead helps her see life through a different lens.

Infants with hemophilia A who received monoclonal antibody emicizumab experienced few bleeding events and no serious complications, a study suggests.

Pearce, professor of epidemiology at the School of Public Health and co-lead of Rogel’s cancer control and population sciences program, reflects on the project and why bringing this study to Michigan is so critical.

The holidays are a great time to discuss your family's medical history. Learn the importance of discussing your family's health history & how to bring it up.

Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite called GTP controls responses to radiation and chemotherapy in an unexpected way.

Technology developed at U-M uses sound waves to destroy tissue, providing a new type of cancer therapy

Sparrow Health System, part of University of Michigan Health, experts release findings in a study of a cancer drug for patients with genetic mutations.